| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Vistagen Therapeutics Inc. | PH94B - (Global) | Social Anxiety Disorder (SAD) | Phase 3 | Ongoing | Intranasal | Psychiatric |
| Vistagen Therapeutics Inc. | PH94B - (Global) | Social Anxiety Disorder (SAD) | Phase 3 | Ongoing | Intranasal | Psychiatric |
| Vistagen Therapeutics Inc. | PH94B - (PALISADE-3) | Social Anxiety Disorder (SAD) | Phase 3 | Data Released | Intranasal | Psychiatric |
| Vistagen Therapeutics Inc. | PH94B - (PALISADE-1) | Social Anxiety Disorder (SAD) | Phase 3 | Trial Completed | Intranasal | Psychiatric |
| Vistagen Therapeutics Inc. | Fasedienol (PH94B) - (PALISADE-2) | Social Anxiety Disorder (SAD) | Phase 3 | Data Released | Intranasal | Psychiatric |
| Vistagen Therapeutics Inc. | AV-101 - (ELEVATE) | Adjunctive Treatment Major Depressive Disorder | Phase 2 | Trial Discontinued | Oral | Psychiatric |
| Vistagen Therapeutics Inc. | PH94B | Adjustment Disorder with Anxiety (AjDA) | Phase 2a | Data Released | Intranasal | Psychiatric |
| Vistagen Therapeutics Inc. | Itruvone (PH10) | Major depressive disorder (MDD) | Phase 2a | Ongoing | Intranasal | Psychiatric |